Macular degeneration trials in Latvia

In Latvia 5 Also abroad 220

5 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Where
Riga, Ventspils
Age
50 years and over
People
304 worldwide
Run by
Amgen
See details and how to joinNCT07614776 · EU 2025-523500-72-00
Phase 3Active, not recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Where
Riga, Ventspils
Age
50 years and over
People
480 worldwide
Run by
4D Molecular Therapeutics
See details and how to joinNCT07064759
Phase 2/3Taking people
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Where
Riga, Ventspils
Age
50 years and over
People
960 worldwide
Run by
EyeBiotech Ltd.
See details and how to joinNCT07440225
Phase 2/3Not yet taking people in Latvia
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
Where
Riga, Ventspils
Age
65 years and over
People
125 worldwide
Run by
Shenzhen Oculgen Biomedical Technology Co. Ltd.
See details and how to join2026-526648-11-00
Phase 2/3Taking people
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
Where
Riga, Ventspils
Age
18 years and over
People
130 worldwide
Run by
Eyebiotech Limited
See details and how to join2025-524575-22-00